AstraZeneca has admitted that its COVID-19 vaccine could cause a rare but deadly blood-clotting condition, potentially exposing the UK pharmaceutical giant to tens of millions in lawsuits brought by ...
AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s cancer drugs despite a potential patent infringement risk. Monday, AZ said ...
After another swing and a miss for AstraZeneca's Fasenra in chronic obstructive pulmonary disease (COPD), the company is pivoting to other options in its portfolio that might have potential to treat ...
A multi-million-pound landmark “vaccine damage” case is set to take place in London’s High Court. The test case is being pursued by Jamie Scott who suffered a severe brain injury in April 2021 after ...
The U.S. Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in combination with pertuzumab for patients with a ...
AstraZeneca's ambitious $80 billion revenue goal by 2030 hinges on oncology growth and successful new drug launches, but faces patent expiries and fierce competition. While current financials and ...
AstraZeneca ($AZN) announced an update on their ongoing clinical study. AstraZeneca Advances Mid-Stage Rheumatoid Arthritis Trial With AZD1163 ...
because Dorji certain If locked contentinjection, Choden side that locked contentcertain economy If people locked contentside dance that during locked contentIf Chili people who locked contentthat ...
U.K.-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) is making news, but not in a good way. Its operations in China were recently rocked when Leon Wang, the company's president in the country -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback